Mumbai, Oct. 14 -- Biocon has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo(R), its biosimilar to the reference product Perjeta(R) (Pertuzumab).

Published by HT Digital Content Services with permission from Capital Market....